ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 149 filers reported holding ASCENDIS PHARMA A/S in Q1 2020. The put-call ratio across all filers is 0.46 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,381 | -99.9% | 82,699 | +50.1% | 0.01% | +57.1% |
| Q2 2020 | $8,147,000 | +41.6% | 55,082 | +7.8% | 0.01% | +16.7% |
| Q1 2020 | $5,752,000 | +38.5% | 51,078 | +71.2% | 0.01% | +100.0% |
| Q4 2019 | $4,152,000 | -42.2% | 29,843 | -60.0% | 0.00% | -50.0% |
| Q3 2019 | $7,185,000 | -65.3% | 74,599 | -58.5% | 0.01% | -66.7% |
| Q2 2019 | $20,704,000 | +98.1% | 179,799 | +102.5% | 0.02% | +80.0% |
| Q1 2019 | $10,452,000 | +252.0% | 88,799 | +111.9% | 0.01% | +233.3% |
| Q3 2018 | $2,969,000 | -29.2% | 41,900 | -33.6% | 0.00% | +50.0% |
| Q2 2018 | $4,192,000 | +865.9% | 63,140 | +850.9% | 0.00% | – |
| Q1 2018 | $434,000 | -30.1% | 6,640 | -57.2% | 0.00% | -100.0% |
| Q4 2017 | $621,000 | -48.8% | 15,500 | -53.7% | 0.00% | 0.0% |
| Q3 2017 | $1,214,000 | +71.7% | 33,500 | +31.5% | 0.00% | 0.0% |
| Q2 2017 | $707,000 | – | 25,470 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |